Unknown PHASE1 INTERVENTIONAL 2-arm NCT02058472

Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers

An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety Following Administration of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers

Sponsor: Dong-A Pharmaceutical Co., Ltd.

Conditions Healthy Adult Volunteers

Interventions G3041 SEVIKAR®

Updated 4 times since 2017 Last updated: Feb 6, 2014 Started: Dec 31, 2013 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Adult Volunteers, this trial is ongoing. The trial is conducted by Dong-A Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A Pharmaceutical Co., Ltd.
Dong-A ST Co., Ltd.

Data source: Dong-A ST Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.